We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’View Video
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin AmericaView Video

Latest Share Chat

Oxford Nanopore maintains outlook after "strong" half-year growth

Mon, 17th Jul 2023 08:40

(Alliance News) - Oxford Nanopore Technologies PLC on Monday said it expects to report half-year growth and the nanopore sequencing firm backed yearly guidance.

Oxford Nanopore said revenue from its core Life Sciences Research Tools segment increased 22% on-year to GBP86 million in the six months to June 30.

Underlying top-line growth from the unit, which does not include Covid-19 sequencing nor revenue from the Emirati Genome Program, is expected to be 46% at constant currency.

The EGP is a programme in Abu Dhabi that will use Oxford Nanopore's sequencing technology to study the genetic make-up Emiratis.

Looking ahead, Oxford Nanopore left annual guidance unchanged. It expects Life Sciences Research Tools revenue to grow 16% to 30% at constant currency for 2023. Revenue at LSRT in 2022 amounted to GBP146.8 million, a 16% rise on a reported basis, and 10% at constant currency. Group revenue overall had totalled GBP198.6 million in 2022, jumping 49%, or 43% at constant currency.

"Underlying LSRT revenue, excluding revenue from the EGP and Covid-19 sequencing, is expected to grow by more than 30% per annum on a constant currency basis in both 2023 and in the medium term," it said.

It targets a gross margin above 60% for the unit this year and more than 65% for the medium-term. The unit's margin in 2022 rose to 56.3% from 53.8% in 2021.

Looking further ahead, and based on "current development and commercialisation plans" it still targets a 2026 breakeven at an adjusted earnings before interest, tax, depreciation and amortisation level.

"We have delivered strong underlying revenue growth in the first half of 2023, as demand for our technology continues to grow from an increasingly broad and diverse base of customers. We have also made considerable progress positioning the business for future growth: launching a number of innovative new products and platform updates that provide users with higher accuracy and richer data than ever before; forming significant collaborations to open up new opportunities in clinical and applied markets; and investing to ensure we have the required levels of inventory to support the continued expansion of our customer base," Chief Executive Officer Gordon Sanghera said.

Shares in the company rose 3.3% to 230.41 pence each in London on Monday morning.

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Related Shares

More News
22 Apr 2024 09:04

LONDON BROKER RATINGS: Jefferies raises B&M to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

12 Apr 2024 15:06

Oxford Nanopore tech used in 'groundbreaking' telomere study

(Sharecast News) - Oxford Nanopore took the wraps off a "groundbreaking" study using its technology on Friday, shedding light on the measurement of hu...

2 Apr 2024 11:15

EARNINGS: EPE Special "cautiously optimistic"; RTW Biotech NAV rises

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reporte...

14 Mar 2024 09:51

LONDON BROKER RATINGS: Kepler Cheuvreux likes Diageo; BofA lifts Man

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

13 Mar 2024 11:02

IP Group net asset value declines amid supply chain issues, inflation

(Alliance News) - IP Group PLC on Wednesday reported a slowed decline in net asset value, citing global issues such as supply chain disruptions and in...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.